Skip to content

Trial Summary

Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that >90% of patients have disease apparent when using PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.



ACTRN/NCT /ethics:


Scientific title:

DECREASE: Phase II DarolutamidE + Consolidation RadiothErapy in Advanced proStatE cancer detected by PSMA

Sponsor / Cooperative group:

Trans Tasman Radiation Oncology Group (TROG)

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2021-06-02
Anticipated End Date2026-06-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorDr Braden Higgs
Recruitment StatusRecruiting